Company news
Onconetix, Inc. news in 2025
Onconetix, Inc.'s news releases, calls and decks from 2025, newest first.
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
September 26, 2025
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 26, 2025
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
September 22, 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)
July 17, 2025
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
July 16, 2025
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
June 16, 2025
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
June 11, 2025
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
May 22, 2025
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
March 24, 2025
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
March 19, 2025